Ethos Technologies Inc. (LIFE) Stock Price & How to Invest

Ethos Technologies runs a three-sided platform connecting consumers, independent agents, and life insurance carriers. A shopper answers underwriting questions online and can be approved for term or whole life coverage in minutes without a medical exam, because Ethos applies its own predictive models to third-party data instead of ordering fluids and attending-physician statements. Ethos does not underwrite anything. It operates as a licensed producer and third-party administrator, placing policies with carrier partners including Banner Life, TruStage and Ameritas, and booking commission revenue on what it places. The same technology stack is licensed to roughly 15,000 active agents who write through the platform, which is the company's third-party channel, and the direct channel sells straight to consumers under the Ethos brand. Cumulative active policies passed 700,000, with 107,847 activated in the June quarter alone.

The investment picture turns on how much of the current growth rate is durable. Revenue in the June 2026 quarter was about $190 million, up 113% year over year and the second consecutive quarter of more than doubling, with the direct channel up 131% and third-party up 90%. Profitability arrived alongside it: about $35 million of adjusted EBITDA at a 19% margin, roughly $19.5 million of GAAP net income, and around $36 million of operating cash flow. Management raised full-year 2026 guidance to roughly $727 million to $731 million of revenue and $119 million to $123 million of adjusted EBITDA, and authorized a $100 million buyback. Read the quarterly cadence in that guidance, though, and the third quarter is guided to about $160 million to $164 million, below the June quarter, with adjusted EBITDA stepping down to $23 million to $25 million. At roughly $2.3 billion of market value against about $587 million of trailing revenue, the multiple already reflects a company growing far faster than the second half is expected to.

Commission revenue is recognized on expected future payments, so GAAP revenue runs well ahead of cash collected, and commission receivables sat at $381.5 million as of June 30, up 51% year over year against a smaller revenue base. That balance is only worth its carrying value if policies persist at the lapse rates assumed, and a persistency shortfall would show up as a revenue reversal rather than a gradual miss. Average revenue per policy fell to roughly $1,758 in the June quarter from about $2,185 in the March quarter on product mix, so headline policy growth and revenue growth can diverge. Trailing GAAP results still show a net loss of roughly $112 million, driven largely by IPO-related stock compensation, which means the reported profitability is one quarter old rather than established. The stock IPO'd at $19 in January 2026 and trades near the top of a $9.45 to $37.17 range, so lock-up expiries and secondary supply from pre-IPO holders like Sequoia and Accel are a real overhang, and the business remains exposed to state insurance regulation and to the privacy and data-handling litigation that has followed the company since a 2022 vendor breach.

8 analysts publish price targets on LIFE, averaging $34.88 against a $36.72 price as of August 2026, or -5.0%. The published targets run from $32.00 to $40.00, a narrow spread, and the ratings split 9 buy, 0 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full LIFE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Ethos Technologies Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Two channels compounding at once. Direct-to-consumer revenue grew 131% year over year in the June quarter while the third-party agent channel grew 90%, so neither is carrying the result alone. The most optimistic published target, $40.00, assumes this works close to its best case.

The case against. Commission revenue is recognized on expected future payments, so GAAP revenue runs well ahead of cash collected, and commission receivables sat at $381.5 million as of June 30, up 51% year over year against a smaller revenue base. The most pessimistic target, $32.00, is roughly what LIFE is worth if this bites instead.

Read the full bull and bear case on LIFE, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Ethos Technologies Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$587M, up ~83% year over year
• Q2 FY2026 revenue: ~$190M, up ~113% year over year
• Adjusted EBITDA (Q2 FY2026): ~$35M, ~19% margin
• Net income (Q2 FY2026): ~$19.5M GAAP, ~$0.30 diluted
• Cash and equivalents: ~$253M as of June 30, 2026
• Market cap: ~$2.3B on ~64M shares

At roughly $2.3 billion of market value, LIFE trades near 4x trailing revenue and about 3.2x the midpoint of its own full-year 2026 guidance. Backing out the $253 million cash balance, enterprise value is close to 17x the $121 million midpoint of guided adjusted EBITDA, which is a growth-company multiple rather than a distributor multiple. The gap between the trailing net loss of about $112 million and a forward earnings multiple near 17 is almost entirely IPO stock compensation working its way out of the comparisons.

Other names that sit close to LIFE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get LIFE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so LIFE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where LIFE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Ethos is a genuinely fast-growing, newly profitable insurance distributor whose price now assumes the doubling continues, which its own second-half guidance does not.

Whether LIFE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LIFE a buy or a sell?, and where the stock could go from here in the LIFE stock forecast.

For income investors, whether LIFE pays a dividend and how the payout looks is covered in does LIFE pay a dividend? And to weigh LIFE against a peer, read the full side-by-side comparisons: LIFE vs BANR and LIFE vs PRU.